Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Lumentum Holdings | Super Micro Computer | Pfizer | |
|---|---|---|---|
| Moat rating | narrow FY2025 10-K (filed 2025-08-19) grounds a narrow rating: on one side ~1,020 U.S. and ~1,100 foreign patents with expirations through 2045 plus vertically integrated wafer fabs (US, UK, Japan, Thailand) behind its laser chips and photonic ICs; on the other, Item 1A states optical communications products 'have increasingly become subject to commoditization' with 'predominantly Asia-based competitors' intensifying pricing pressure and a historical 'continued decline of average selling prices' expected to continue. | narrow The FY2026 10-K describes a genuine but bounded advantage. On the asset side the filing claims a modular Server Building Block Solutions architecture, over 3,500 R&D employees, in-house design control over many sub-systems, and that Supermicro believes it is 'the only major server, storage, and accelerated compute platform vendor that designs, develops, and manufactures a significant portion of its systems in the United States.' Against that, the same filing calls its market 'highly competitive, rapidly evolving,' concedes that 'most of our competitors have longer operating histories, significantly greater resources, greater name recognition, or deeper market penetration,' reports intensified competition from 'predominantly Asia-based' entrants 'leading to pricing pressure,' and states that pricing pressure has produced 'a continued decline of average selling prices across our business and we expect that these historical trends will continue.' It also disclaims patent dependence outright. A durable-but-shallow advantage in time-to-market and integration, sitting on top of a commoditizing box business, is narrow rather than wide. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | intangibles ip Per the FY2025 10-K, the moat rests on intangibles/IP and process know-how: patent portfolio (~1,020 U.S. / ~1,100 foreign, ~780 pending), InP laser and photonic-integrated-circuit technology (Oclaro, NeoPhotonics acquisitions), coherent DSP/ASIC lines (IPG telecom transmission acquisition), and its own wafer fabrication, assembly and test facilities — the company states it does not broadly license its IP absent adequate consideration or cross-licenses. | cost scale The filing locates the advantage in design-and-manufacturing scale, not in IP or lock-in. It says the company manufactures the majority of its systems at its San Jose headquarters with assembly, test and QC also in Taiwan, the Netherlands and Malaysia, and that this structure lets it 'reduce time to delivery, mitigate the impact of tariffs and regional costs, and reduce overall manufacturing costs.' Its own list of principal competitive factors includes 'cost-effective design and manufacturing' and 'sufficient manufacturing capacity necessary to support market demand.' Intangibles are explicitly ruled out as the source: 'neither our business as a whole nor any of our principal businesses are materially dependent on a single patent,' with reliance placed 'primarily on trade secrets, technical know-how.' Switching costs are weak by the filing's own account: it 'typically sell[s] products pursuant to purchase orders rather than long-term purchase commitments,' and customers 'have, and others may in the future, cancel or defer purchase orders on short notice without incurring a significant penalty.' | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | co leader Mixed by layer: the FY2025 10-K self-describes Lumentum as 'a leading provider of optical and photonic products... recognized as an industry leader based on revenue and market share' (company's own characterization), while LightCounting's May 2026 optical vendor landscape places Lumentum near the bottom of its transceiver-only Top 10 — noting the list 'accounts for sales of optical transceivers only, excluding all other products, which explains lower rankings of Coherent and Lumentum' and that 'Neither CIG nor Lumentum plan to stay at the bottom of the list for much longer.' Co-leader in optical components/chips; follower in merchant transceiver modules behind Innolight and Eoptolink. | at parity The filing claims no market-share leadership and gives no share figure. It states 'we believe that we compete favorably with respect to most of these factors' while immediately conceding that 'most of our competitors have longer operating histories, significantly greater resources, greater name recognition, or deeper market penetration,' naming Cisco, Dell, Hewlett-Packard Enterprise and Lenovo plus ODMs Foxconn, Quanta Computer and Wiwynn. The one leadership claim it does make is narrow and structural — that it believes it is the only major vendor in its class manufacturing a significant portion of its systems in the United States — plus a stated goal (not an achievement) to 'be the first to market with superior product designs.' Competing favorably against larger, better-penetrated rivals without asserting share leadership is parity, not leadership. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | moderate The May 5, 2026 Q3 FY2026 earnings release shows current pricing traction — CEO cites 'operational rigor, pricing discipline, and product mix' behind a 540 bps sequential non-GAAP gross-margin gain to 47.9% — but the FY2025 10-K states pricing pressures 'have led to a continued decline of average selling prices across our business and we expect that these historical trends will continue,' so power is cyclical/mix-driven rather than structural. | weak The filing states pricing pressure explicitly and repeatedly. 'Historically, these pricing pressures have led to a continued decline of average selling prices across our business and we expect that these historical trends will continue.' On large orders: 'Large orders are generally subject to intense competition and pricing pressure which can have an adverse impact on our margins and results of operations.' It concedes it has 'accepted customer orders with various types of component pricing protection' which 'increased our exposure to component pricing fluctuations and have adversely affected our financial results in certain quarters,' and that FY2026 industry supply constraints in memory, storage, GPUs and CPUs affected 'the pricing of these items.' Its stated remedy is aspirational rather than realized: it 'must continue to develop more advanced, differentiated products that command a premium.' The filing gives no gross-margin trend in Item 1/1A; margin appears there only as a downside — excess or obsolete inventory 'would reduce our gross margin.' | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | Lumentum is an optical and photonics supplier whose FY2025 10-K describes two segments: Cloud & Networking ($1,410.8M of $1,645.0M FY2025 revenue) spanning datacom transceivers (Cloud Light), laser chips/EML transmitters, photonic ICs, co-packaged optics, optical circuit switches, and telecom transport (ROADMs, tunable and coherent components, pump lasers); and Industrial Tech ($234.2M) in fiber/ultrafast/diode lasers and 3D-sensing VCSELs. AI datacenter demand has inflected the business: the May 5, 2026 Q3 FY2026 release reports record revenue of $808.4M, up 90.1% YoY, with non-GAAP gross margin of 47.9% and the CEO crediting laser-chip strength, 'scale-across' components (pump lasers, narrow-linewidth laser assemblies), and pricing discipline, with co-packaged optics and optical circuit switches named as the next growth drivers. The moat is real but narrow: differentiation lives in photonic chip IP and vertical fab integration, while the transceiver-module layer commoditizes — LightCounting's May 2026 vendor landscape ranks Lumentum near the bottom of its transceiver-only Top 10 behind Innolight ($5.3B 2025 revenue) and Eoptolink, and Cignal AI (April 21, 2026) sizes 2025 datacom optical component revenue above $19B, up more than 70%, a market where scale rivals are growing as fast or faster. Customer concentration (top customers 16.0% and 15.4% of FY2025 revenue) and the 10-K's ASP-decline language cap the rating below wide. | Supermicro's edge, as its FY2026 10-K frames it, is speed and integration built on a common modular parts bin: it works with NVIDIA, Intel and AMD to 'align the design of our new products with their product release schedules,' then 'quickly assemble a broad portfolio of solutions by leveraging common building blocks across product lines.' During FY2026 it pushed that advantage up a level, growing Data Center Building Block Solutions to 'more than ten key subsystems' — coolant distribution units, heat exchangers, power shelves, switching, management software — and deploying DLC-2 liquid cooling the filing credits with up to 98% per-rack heat capture and up to 40% lower data center power draw. But the filing's competition and risk discussion is candid that this sits inside a price-taking market: ASPs decline structurally, one customer exceeded 10% of net sales in FY2026, and ODMs 'benefit from their scale and very low-cost manufacturing' while increasingly selling their own brands. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Upstream photonics supplier into AI/cloud datacenter and telecom infrastructure: sells transceivers, laser chips, CPO components and OCS to cloud operators, AI infrastructure providers and NEMs, and also supplies components to transceiver makers who compete with it ('Some of these competitors are also our customers' — FY2025 10-K). Concentrated demand: Customer A 16.0% and Customer B 15.4% of FY2025 net revenue; manufacturing concentrated in Thailand, China, UK, Slovenia, Japan and US with sole/limited-source component exposure. | Downstream system integrator: it converts third-party accelerators and CPUs (NVIDIA Blackwell/GB300 NVL72, AMD Instinct MI350, Intel Xeon 6) into validated racks, liquid cooling and full data-center building blocks sold to cloud service providers and enterprises. The AI angle is central, not incidental — the filing devotes a risk factor titled 'The AI industry has driven a significant portion of our recent success' and states 'A portion of the recent success of our server and storage solutions has been dependent on the integration of our products and services within the AI industry.' | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.13 at weight 0.20 · swarm bullish Editorial prior, not backtested. | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |